Roche To Build RWE Cancer Data Extraction Role With Flatiron Buy

Acquisition reflects that regulatory-grade real-world evidence will play increasing role in drug discovery, development, commercialization and reimbursement.

Evidence
Roche Sees Flatiron As Real-World Evidence Therapeutic Link • Source: Shutterstock

Roche says its planned purchase of cancer data specialist Flatiron Health Inc. will help the Swiss group progress its own pipeline while helping to design the use of real-world evidence (RWE) to set new industry standards for oncology research and development.

The acquisition, announced Feb. 15, stems from an existing partnership between the two companies,with Roche already holding a 12.6% stake in Flatiron. Roche said it will pay $1

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business

In Brief: US FDA Delay Sends Biohaven Shares Down

 

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By 

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.